Voxelotor
Brand name: Oxbryta
Rank #332 of 500 drugs by total cost
$31.5M
Total Cost
2,707
Total Claims
$31.5M
Total Cost
115
Prescribers
$12K
Cost per Claim
76
Beneficiaries
2,774
30-Day Fills
$274K
Avg Cost/Provider
24
Avg Claims/Provider
About Voxelotor
Voxelotor (sold as Oxbryta) was prescribed 2,707 times by 115 Medicare Part D providers in 2023, costing the program $31.5M. At $12K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 329 | Empagliflozin/Linagliptin (Glyxambi) | $32.6M | 34,331 |
| 330 | Methotrexate Sodium (Methotrexate) | $32.4M | 911,965 |
| 331 | Bumetanide (Bumetanide) | $32.4M | 735,077 |
| 332 | Voxelotor (Oxbryta) | $31.5M | 2,707 |
| 333 | Rivastigmine (Rivastigmine) | $31.4M | 118,567 |
| 334 | Zolpidem Tartrate (Zolpidem Tartrate) | $31.3M | 3,144,599 |
| 335 | Lorazepam (Lorazepam) | $31.3M | 3,237,827 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology